Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of asenapine, which is partially metabolized by the isoenzyme. According to the product labeling, administration of asenapine (5 mg single dose) in combination with the potent CYP450 1A2 inhibitor fluvoxamine (25 mg twice daily for 8 days) resulted in a 13% increase in asenapine peak plasma concentration (Cmax) and a 29% increase in systemic exposure (AUC). The full therapeutic dose of fluvoxamine would be expected to cause a greater increase in asenapine plasma concentrations.

MANAGEMENT: Caution is advised if asenapine is prescribed in combination with CYP450 1A2 inhibitors. Pharmacologic response to asenapine should be monitored more closely whenever a CYP450 1A2 inhibitor is added to or withdrawn from therapy, and the asenapine dosage adjusted as necessary.

Alcohol can increase the nervous system side effects of asenapine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with asenapine. Do not use more than the recommended dose of asenapine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.

Information for this minor interaction is available on the professional version.